# US 9,359,332 B2 · Processes for the preparation of substituted quinazolines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,359,332 B2
- Document ID: US9359332B2
- Status: Granted
- Kind: B2
- Application number: 14/060,123
- Filed: 2013-10-22
- Published: 2014-06-05
- Granted: 2016-06-07
- Earliest claimed: 2002-07-15
- Assignees: Symphony Evolution, Inc.
- Applicants: Symphony Evolution, Inc.
- Inventors: Kenneth D. Rice; Neel K. Anand; Joerg Bussenius; Simona Costanzo; Abigail R. Kennedy; Csaba J. Peto; Tsze H. Tsang; Charles M. Blazey
- Web page: https://patentgrep.com/patent/US9359332B2

## CPC

- C07D 403/12: linked by a chain containing hetero atoms as chain links
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/5383: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/5513: 1,4-Benzodiazepines, e.g. diazepam {or clozapine}
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/94: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07D 451/06: Oxygen atoms
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- C07D 493/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides compounds for modulating receptor kinase activity, particularly ephrin and EGFR, and methods of treating diseases mediated by receptor kinase activity utilizing the compounds and pharmaceutical compositions thereof. The compounds are generally of formula (I): Diseases mediated by receptor kinase activity include, but are not limited to, diseases characterized in part by abnormal levels of cell proliferation (i.e. tumor growth), programmed cell death (apoptosis), cell migration and invasion and angiogenesis associated with tumor growth. Compounds of the invention include “spectrum selective” kinase modulators, compounds that inhibit, regulate and/or modulate signal transduction across subfamilies of receptor-type tyrosine kinases, including ephrin and EGFR. Also disclosed are methods of making compounds for formula 8: comprising introducing group E2 into a compound of formula 7: wherein Ar, Z, P, and E2 are defined herein.

## Claims

### Claim 1

A process for preparing a compound of the formula 8,
or a salt thereof, wherein:
E2 is
wherein the process comprises
(a) O-alkylating a compound of formula 7,
in the presence of a solvent and a base, wherein
R is an N-protecting group that is tert-butoxycarbonyl, carbobenzyloxy, allyloxycarbonyl, acetyl, trifluoroacetyl, benzyl or p-toluenesulfonyl, and
R′ is H or an O-protecting group that is p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl or 2-mesitylsulfonyl,
to provide
wherein R is the N-protecting group that is tert-butoxycarbonyl, carbobenzyloxy, allyloxycarbonyl, acetyl, trifluoroacetyl, benzyl or p-toluenesulfonyl;
(b) deprotecting the compound formed in (a) to provide
(c) N-methylating the compound formed in (b) to provide the compound of formula 8,
and
(d) optionally converting the compound of formula 8 into the salt of the compound of formula 8.

### Claim 2 (depends on 1)

The process according to claim 1, wherein (a) comprises reacting
or a salt thereof,
with the compound of formula 7:
or a salt thereof,
to provide
or a salt thereof.

### Claim 3 (depends on 1)

The process according to claim 1, wherein (b) comprises deprotecting
or a salt thereof,
to provide
or a salt thereof.

### Claim 4 (depends on 1)

The process according to claim 1, where the compound of formula 8 is:
or a salt thereof.

### Claim 5 (depends on 4)

The process according to claim 4, wherein the solvent is N,N-dimethylacetamide.

### Claim 6 (depends on 4)

The process according to claim 4, wherein the base is potassium carbonate.

### Claim 7 (depends on 1)

The process according to claim 1, where the compound of formula 8 is:
or a salt thereof.

### Claim 8

A process for preparing a compound of the formula 8:
or a salt thereof, wherein
E2 is
where the process comprises
(a) O-alkylating a compound of the formula 7,
in the presence of a solvent and a base, wherein
R is an N-protecting group that is tert-butoxycarbonyl, carbobenzyloxy, allyloxycarbonyl, acetyl, trifluoroacetyl, benzyl or p-toluenesulfonyl, and
R′ is H or an O-protecting group that is p-toluenesulfonyl, methanesulfonyl, trifluoromethanesulfonyl or 2-mesitylsulfonyl,
to provide
wherein R is the N-protecting group that is tert-butoxycarbonyl, carbobenzyloxy, allyloxycarbonyl, acetyl, trifluoroacetyl, benzyl or p-toluenesulfonyl;
(b) deprotecting the compound formed in (a) to provide
(c) N-methylating the compound formed in (b) to provide the compound of formula 8,
and
(d) optionally converting the compound of formula 8 into the salt of the compound of formula 8.

### Claim 9 (depends on 8)

The process according to claim 8, wherein (a) comprises reacting
or a salt thereof,
with the compound of formula 7,
or a salt thereof,
to provide
or a salt thereof.

### Claim 10 (depends on 8)

The process according to claim 8, wherein (b) comprises deprotecting
or salt thereof,
to provide
or a salt thereof.

### Claim 11 (depends on 8)

The process according to claim 8, wherein the solvent is N,N-dimethylacetamide.

### Claim 12 (depends on 8)

The process according to claim 8, wherein the base is potassium carbonate.
